Prednisone on the threshold of rational use in the treatment of rheumatoid arthritis

Abstract

This is a review of the evolution of the use prednisone in the treatment of rheumatoid arthritis (RA). Cortisone was introduced in 1949 and shortly thereafter, the Mayo investigators found that low divided doses with slow tapering were effective and caused fewer side effects. In 1959, a British double blind 2 year study of prednisolone treatment in early RA demonstrated effectiveness and reduced bony erosions. This experience was lost over time and empiricism and efforts to reduce side effects dominated practice for the next 35 years. Since 1995, a number of controlled studies of low single daily doses of prednisone in early RA have been reported by European investigators. They have shown clinical improvement, reduced bony erosions, augmentation of the effect of dmards and few side effects. During the last 25 years, the molecular actions of glucocorticoids have been elucidated. The time relationship of the dose to the biologic and clinical effects has been established. As a result of the information on the diurnal effect of glucocorticoids and the documentation of the effect occurring 5-6 hours after the dose and dissipating by 24 hours, a delayed release preparation of prednisone has been developed. With the rediscovery of the effectiveness of low single daily morning dose of prednisone in early RA by controlled studies and the demonstration of the onset and duration of the clinical effect of low dose of prednisone, it is now possible to use low doses of prednisone rationally and effectively in the treatment of RA. It remains to be determined whether a single morning, single evening or a twice a day low dose is the most effective and safe. It is doubtful if the new delayed release prednisone is any more effective than the usual immediate release prednisone if given at the same time.

Share and Cite:

Conn, D. (2013) Prednisone on the threshold of rational use in the treatment of rheumatoid arthritis. Health, 5, 1-5. doi: 10.4236/health.2013.58A1001.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Physicians Desk Reference (2013) Rayos. A Concise Monograph. http://fda.net/
[2] Buttgereit, F., Doering, G., Schaeffler, A., Witte, S., Sierakowski, S., Gromnica-Ihle, E., et al., (2008) Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (Capra-1): A double-blind, randomized controlled trial. The Lancet, 371, 205-214. doi:10.1016/S0140-6736(08)60132-4
[3] Straub, R.H. and Cutulo, M. (2007) Circadian rhythms in rheumatoid arthritis. Arthritis & Rheumatism, 56, 399-408. doi:10.1002/art.22368
[4] Arvidson, N.G., Gudbjornsson, B., Larsson, A. and Hallgren, R. (1997) The timing of glucocorticoid administration in rheumatoid arthritis. Annals of the Rheumatic Diseases, 56, 27-31. doi:10.1136/ard.56.1.27
[5] Hench, P.S., Kendall, E.C., Slocumb, C.H. and Polley, H.F. (1949) The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: Compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proceedings of the Staff Meetings of the Mayo Clinic, 24, 181-197.
[6] Ward, L.M., Slocumb, C.H., Polley, H.F., Lowman, E.W. and Hench, P.S. (1951) Clinical effects of cortisone administered orally to patients with rheumatoid arthritis. Proceedings of the Staff Meetings of the Mayo Clinic, 26, 361-370.
[7] Ward, L.M., Polley, H.F., Power, M.H., Mason, H.L., Slocumb, C.H. and Hench, P.S. (1958) Prednisone in rheumatoid arthritis: Metabolic and clinical effects. Annals of the Rheumatic Diseases, 17, 145-159. doi:10.1136/ard.17.2.145
[8] Report by the Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, ACTH, and other Therapeutic Measures in Chronic Rheumatic Diseases (1959) A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Annals of the Rheumatic Diseases, 18, 173-188. doi:10.1136/ard.18.3.173
[9] Harter, J.G., Reddy, W.J. and Thorn, G.W. (1963) Studies on an intermittent corticosteroid dosage regimen. The New England Journal of Medicine, 269, 591-596. doi:10.1056/NEJM196309192691201
[10] Black, R.L. (1966) The use of synthetic corticosteroids in rheumatoid arthritis. In: Hollander, J.L., Ed., Arthritis and Allied Conditions, 7th Edition, Lea and Febiger, Philadelphia, 364-380.
[11] Hess, E.V. and Goldman, J.A. (1972) Corticosteroids and corticotropin in the therapy of rheumatoid arthritis. In: Hollander, J.L. and McCarty, D.J., Eds., Arthritis and Allied Conditions, 8th Edition, Lea and Febiger, Philadelphia, 495-516.
[12] Lightfoot Jr., R.W. (1979) Treatment of rheumatoid arthritis. In: McCarty, D.J., Ed., Arthritis and Allied Conditions, 9th Edition, Lea and Febiger, Philadelphia, 513-518.
[13] Ruddy (1985) The management of rheumatoid arthritis. In: Kelley, W.N., Harris Jr., E.D., Ruddy, S. and Sledge, C.B., Eds., Textbook of Rheumatology, 2nd Edition, W.B. Saunders Company, Philadelphia, 979-992.
[14] Harris Jr., E.D. (1993) The management of rheumatoid arthritis. In: Kelley, W.N., Harris Jr., E.D., Ruddy, S. and Sledge, C.B., Eds., Textbook of Rheumatology, 4th Edition, W.B. Saunders Company, Philadelphia, 912-923.
[15] Kirwan, J.R. (1995) The effect of glucocorticoids on joint destruction in rheumatoid arthritis: the arthritis and rheumatism council low-dose glucocorticoid study group. The New England Journal of Medicine, 333, 142-146. doi:10.1056/NEJM199507203330302
[16] van Everdingen, A.A., Jacobs, J.W.G., Siewertsz van Reesema, D.R. and Bijlsma, W.J. (2002) Low-dose prednisone therapy for patients with early active rheumatoid arthritis: Clinical efficacy, diseasemodifying properties, and side effects. Annals of Internal Medicine, 136, 1-12. doi:10.7326/0003-4819-136-1-200201010-00006
[17] Svensson, B., Boonen, A., Albertsson, K., van der Heijde, D., Keller, C. and Hafstrom, I. (2005) Low-dose prednisolone in addition to the initial diesease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate. Arthritis & Rheumatism, 52, 3360-3370. doi:10.1002/art.21298
[18] Wassenberg, S., Rau, R., Steinfeld, P. and Zeidler, H. (2005) Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years. Arthritis & Rheumatism, 52, 3371-3380. doi:10.1002/art.21421
[19] Bakker, M., Jacobs, J.W.G., Weising, P.M.J., Verstappen, SMM, Tekstra, J., Ton, E., et al. (2012) Low-dose prednisone inclusion in methotrexate-based tight control strategy for early rheumatoid arthritis. Annals of Internal Medicine, 156, 329-339. doi:10.7326/0003-4819-156-5-201203060-00004
[20] Da Silva, J.A.P., Jacobs, J.W.G., Kirwan, J.R., Boers, M., Saag, K.G., Ines, L.B.S., et al. (2006) Safety of low dose glucocorticoid treatment in rheumatoid arthritis: Published evidence and prospective trial data. Annals of the Rheumatic Diseases, 65, 285-293. doi:10.1136/ard.2005.038638
[21] Buttgereit, F., Straub, R.H., Wehling, M. and Burmester, G.R. (2004) Glucocorticoids in the treatment of rheumatic diseases. Arthritis & Rheumatism, 50, 3408-3417. doi:10.1002/art.20583
[22] Cidlowski, J.A. (2005) Antiinflammatory action of glucocorticoids—New mechanisms for old drugs. The New England Journal of Medicine, 353, 1711-1723. doi:10.1056/NEJMra050541
[23] Chrousos, G.P. (2009) The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. The New England Journal of Medicine, 332, 1351-1362.
[24] Straub, R.H., Paimela, L., Peltomaa, R., Scholmerich, J. and Leirisalo-Repo, M. (2002) Inadequate low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. Arthritis & Rheumatism, 46, 654-662. doi:10.1002/art.10177
[25] Buttgereit, F., Hehta, D., Kirwan, J., Szechinski, J., Boers, M., Alten, R., et al. (2013) Low-dose prednisone chronotherapy for rheumatoid arthritis: A randomized clinical trial (Capra-2). Annals of the Rheumatic Diseases, 72, 204-210. doi:10.1136/annrheumdis-2011-201067

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.